

ROS-Targeting Nanozyme Drug Candidate for 2nd Degree Burn Wounds



OTHERS	Preclinical
Product Type	Others-Synth.
Indication	Deep second-degree burns in adults.
Target	Reactive oxygen species (ROS).
MoA(Mechanism of Action)	HT-0203 accelerates the wound healing cycle of the burn wounds via catalytic ROS scavenging: a continuous redox-based reduction of ROS. HT-0203 inhibits the inflammatory responses at the wound and promotes the tissue repair and re-epithelialization by increasing the angiogenesis and tissue regeneration factors
Competitiveness	First-in-Class MoA: Continuously scavenges upstream ROS (superoxide) to prevent burn wound progression, overcoming the limitations of conventional ointments. Superior Efficacy: Demonstrated significantly higher rates of wound closure (approx. 52%) and anti-inflammatory effects compared to SoC treatments. High Commercial Viability: Strong competitive edge in supply chain (stability, and cost-effectiveness) compared to expensive biologic/cell therapies.
Development Stage	Preclinical
Route of Administration	Topical

Any unauthorized distribution or reproduction of this material is strictly prohibited.